Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice

被引:57
作者
Gomez-Sintes, Raquel
Hernandez, Felix
Bortolozzi, Analia
Artigas, Francesc
Avila, Jesus
Zaratin, Paola
Gotteland, Jean Pierre
Lucas, Jose J.
机构
[1] UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain
[2] CSIC, Inst Invest Biomed Barcelona, IDIBAPS, Dept Neuroquim & Neurofarmacol, Barcelona, Spain
[3] Ist Ric Biomed A Marxer, LCG, RBM Serono Discovery, Colleretto Giacosa, Italy
[4] Merck Serono Int, Geneva, Switzerland
关键词
apoptosis; conditional; dominant negative; GSK-3; transgenic;
D O I
10.1038/sj.emboj.7601725
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increased glycogen synthase kinase-3 (GSK-3) activity is believed to contribute to the etiology of chronic disorders like Alzheimer's disease and diabetes, thus supporting therapeutic potential of GSK-3 inhibitors. However, sustained GSK-3 inhibition might induce tumorigenesis through beta-catenin-APC dysregulation. Besides, sustained in vivo inhibition by genetic means (constitutive knockout mice) revealed unexpected embryonic lethality due to massive hepatocyte apoptosis. Here, we have generated transgenic mice with conditional (tetracycline system) expression of dominant-negative-GSK-3 as an alternative genetic approach to predict the outcome of chronic GSK-3 inhibition, either per se, or in combination with mouse models of disease. By choosing a postnatal neuron-specific promoter, here we specifically address the neurological consequences. Tet/ DN-GSK-3 mice showed increased neuronal apoptosis and impaired motor coordination. Interestingly, DN-GSK-3 expression shut-down restored normal GSK-3 activity and re-established normal incidence of apoptosis and motor coordination. These results reveal the importance of intact GSK-3 activity for adult neuron viability and physiology and warn of potential neurological toxicity of GSK-3 pharmacological inhibition beyond physiological levels. Interestingly, the reversibility data also suggest that unwanted side effects are likely to revert if excessive GSK-3 inhibition is halted.
引用
收藏
页码:2743 / 2754
页数:12
相关论文
共 49 条
[1]   beta-catenin is a target for the ubiquitin-proteasome pathway [J].
Aberle, H ;
Bauer, A ;
Stappert, J ;
Kispert, A ;
Kemler, R .
EMBO JOURNAL, 1997, 16 (13) :3797-3804
[2]   Lithium protects cultured neurons against β-amyloid-induced neurodegeneration [J].
Alvarez, G ;
Muñoz-Montaño, JR ;
Satrústegui, J ;
Avila, J ;
Bogónez, E ;
Díaz-Nido, J .
FEBS LETTERS, 1999, 453 (03) :260-264
[3]   Role of tau protein in both physiological and pathological conditions [J].
Avila, J ;
Lucas, JJ ;
Pérez, M ;
Hernández, F .
PHYSIOLOGICAL REVIEWS, 2004, 84 (02) :361-384
[4]   Atm-deficient mice: A paradigm of ataxia telangiectasia [J].
Barlow, C ;
Hirotsune, S ;
Paylor, R ;
Liyanage, M ;
Eckhaus, M ;
Collins, F ;
Shiloh, Y ;
Crawley, JN ;
Ried, T ;
Tagle, D ;
WynshawBoris, A .
CELL, 1996, 86 (01) :159-171
[5]   Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade [J].
Beaulieu, JM ;
Sotnikova, TD ;
Yao, WD ;
Kockeritz, L ;
Woodgett, JR ;
Gainetdinov, RR ;
Caron, MG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (14) :5099-5104
[6]   The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways [J].
Beurel, Eleonore ;
Jope, Richard S. .
PROGRESS IN NEUROBIOLOGY, 2006, 79 (04) :173-189
[7]   LITHIUM-CHLORIDE POTENTIATES TUMOR NECROSIS FACTOR-MEDIATED CYTO-TOXICITY INVITRO AND INVIVO [J].
BEYAERT, R ;
VANHAESEBROECK, B ;
SUFFYS, P ;
VANROY, F ;
FIERS, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (23) :9494-9498
[8]   GSK3 inhibitors: Development and therapeutic potential [J].
Cohen, P ;
Goedert, M .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (06) :479-487
[9]   Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease [J].
Díaz-Hernández, M ;
Torres-Peraza, J ;
Salvatori-Abarca, A ;
Morán, MA ;
Gómez-Ramos, P ;
Alberch, J ;
Lucas, JJ .
JOURNAL OF NEUROSCIENCE, 2005, 25 (42) :9773-9781
[10]   Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity:: Role in atypical antipsychotic action [J].
Díaz-Mataix, L ;
Scorza, MC ;
Bortolozzi, A ;
Toth, M ;
Celada, P ;
Artigas, F .
JOURNAL OF NEUROSCIENCE, 2005, 25 (47) :10831-10843